Pared-down J&J confident in growth drivers as Stelara patent cliff looms

As J&J prepares to cleave off its consumer health business into a separate entity, incoming CEO Joaquin Duato will be tasked with leading a slimmed-down biopharma anchored by innovative therapeutics, with new growth drivers amid a looming patent cliff.

Johnson & Johnson (NYSE:JNJ) said Friday that its innovative business, expected to generate about $77 billion in worldwide 2021 sales, will retain the company’s pharmaceutical and medical device segments, and will still be the world’s largest healthcare company. Consumer brands including over-the-counter medicines, self-care and essential health products, and skin and beauty products will be housed in the new, as-yet-unnamed company...